RayKnowChina Research Map
Shortlist0

RecruitingB-cell acute lymphoblastic leukaemiaPhase 2

Registered title, quoted from ClinicalTrials.gov

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

An open trial on B-cell acute lymphoblastic leukaemia, registered on ClinicalTrials.gov. Led by Beijing Tongren Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Tongren Hospital首都医科大学附属北京同仁医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06081478, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 14 years to 85 years; sex: all

    Registered eligibility fields

  2. ECOG-PS score=0-2;

    Inclusion criterion 4

  3. Liver: TBIL≤3ULN,AST ≤2.5ULN,ALT ≤2.5ULN;

    Inclusion criterion 7

    bone marrow: WBC ≥ 3.0×10e9/L, Hb ≥80 g/L, PLT ≥ 50×10e9/L;

    Inclusion criterion 9

  4. Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test);

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06081478, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 14 years to 85 years, expected survival > 3 months;
  • CD19/CD22 positive B-cell lymphoma or B-ALL;
  • relapsed or refractory to standard first-line treatment;
  • ECOG-PS score=0-2;
  • Having at least one measurable lesions;
  • Cardiac function: 1-2 levels;
  • Liver: TBIL≤3ULN,AST ≤2.5ULN,ALT ≤2.5ULN;
  • kidney: Cr≤1.25ULN;
  • bone marrow: WBC ≥ 3.0×10e9/L, Hb ≥80 g/L, PLT ≥ 50×10e9/L;
  • No serious allergic constitution;
  • No other serious diseases that conflicts with the clinical program;
  • No other cancer history;
  • No serious mental disorder;
  • Informed consent is signed by a subject or his lineal relation.

Exclusion Criteria:

  • Pregnant or lactating women; (female participants of reproductive potential must have a negative serum or urine pregnancy test);
  • Uncontrolled active infection, HIV infection, syphilis serology reaction positive;
  • Active hepatitis B or hepatitis C infection;
  • Recent or current use of glucocorticoid or other immunosuppressor;
  • With severe cardiac, liver, renal insufficiency, diabetes and other diseases;
  • Participate in other clinical research in the past three months;
  • previously treatment with any gene therapy products;
  • Researchers think of that does not fit to participate in the study, or other cases that affect the clinical trial results.

Quoted from ClinicalTrials.gov, NCT06081478, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06081478, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06081478